Skip to main content

BioNTech SE (BNTX) Stock

BioNTech SE Stock Details, Movements and Public Alerts

Stock Details

BioNTech SE (BNTX), a prominent company in the healthcare sector within the biotechnology industry, is based in USA and primarily trades on the NASDAQ.Currently, the stock is trading at $116.81. Over the past 52 weeks, it has ranged between $79.52 and $124.00. This places the current price at 94.2% of its 52-week high and 46.9% above its 52-week low. Recent trading volume was recorded at 2,960,585. The 14-day Relative Strength Index (RSI) stands at 75.43, suggesting overbought conditions. The stock is currently trading above its 50-day moving average of $92.65 by 26.08%. Similarly, it is above its 200-day moving average of $97.52 by 19.78%. The MACD histogram is 1.94, indicating bullish momentum (MACD Line: 2.90, Signal Line: 0.96). There are currently 2 active alerts set for BNTX by users.

52-Week Range

$124.00 - $79.52

-5.80% from high · +46.89% from low

Avg Daily Volume

1,494,770

20-day average

100-day avg: 1,026,261

Fundamentals

Valuation Metrics

P/E Ratio (TTM)

N/A

Forward P/E

7.04

PEG Ratio

0.05

Potentially undervalued

Price to Book

1.13

EV/EBITDA

32.70

EPS (TTM)

-$9.47

Price to Sales

10.72

Beta

1.28

Similar volatility to market

Q:How is BNTX valued relative to its earnings and growth?
Valuation data is not available for this stock.
Q:What is BNTX's risk profile compared to the market?
With a beta of 1.28, BioNTech SE is roughly as volatile as the market, moving in line with broad market trends. This moderate beta suggests the stock offers market-level returns without excessive volatility. The price-to-book ratio of 1.13 shows investors value the company above its book value, which often reflects intangible assets or growth prospects.

Performance & Growth

Profit Margin

-63.60%

Operating Margin

-807.00%

EBITDA

$-1,380,800,000

Return on Equity

-9.30%

Return on Assets

-5.41%

Revenue Growth (YoY)

-59.50%

Earnings Growth (YoY)

-43.20%

Q:How profitable and efficient is BNTX's business model?
BioNTech SE achieves a profit margin of -63.60%, meaning it retains $-63.60 from every $100 in revenue after all expenses. This relatively low margin suggests the company operates in a competitive environment or high-cost industry where profitability is challenging. The operating margin of -807.00% reveals how efficiently the company runs its core business operations before interest and taxes. With ROE at -9.30% and ROA at -5.41%, the company achieves moderate returns on invested capital.
Q:What are BNTX's recent growth trends?
BioNTech SE's revenue declined by 59.50% year-over-year, indicating challenges in maintaining sales momentum. This contraction may reflect market headwinds, competitive pressures, or strategic transitions. Earnings decreased by 43.20% year-over-year, outpacing revenue growth through improved margins. These growth metrics should be evaluated against BIOTECHNOLOGY industry averages for proper context.

Company Size & Market

Market Cap

$28.4B

Revenue (TTM)

$2.65B

Revenue/Share (TTM)

$10.69

Shares Outstanding

251.20M

Book Value/Share

$81.83

Asset Type

Common Stock

Q:What is BNTX's market capitalization and position?
BioNTech SE has a market capitalization of $28.4B, classifying it as a large-cap stock ($10B-$200B). Large-caps are typically industry leaders with established business models, offering a balance of stability and growth potential. They often provide dividend income and are core holdings in institutional portfolios. With 251.20M shares outstanding, the company's ownership is relatively concentrated. As a participant in the BIOTECHNOLOGY industry, it competes with other firms in this sector.
Q:How does BNTX's price compare to its book value?
BioNTech SE's book value per share is $81.83, while the current stock price is $116.81, resulting in a price-to-book (P/B) ratio of 1.43. This reasonable premium to book value suggests the market values the company's earnings power and intangible assets appropriately. Most profitable companies trade between 1-3x book value. As a common stock, this represents equity ownership with voting rights.

Analyst Ratings

Analyst Target Price

$121.75

4.23% upside potential

Analyst Recommendations

Strong Buy

1

Buy

14

Hold

5

Sell

0

Strong Sell

0

Q:How reliable are analyst predictions for BNTX?
20 analysts cover BNTX with 75% recommending buy/strong buy ratings. Analyst predictions have mixed reliability - studies show consensus rarely beats market returns consistently. The strong bullish consensus may already be priced in. The consensus target of $121.75 implies 4.2% upside, but targets are often adjusted to follow price moves rather than predict them.
Q:What is the Wall Street consensus on BNTX?
Current analyst recommendations:1 Strong Buy, 14 Buy, 5 Hold, 00The bullish tilt suggests optimism about future prospects, though investors should conduct independent research.Remember that analyst opinions often lag price movements and can be influenced by investment banking relationships.

Fundamentals last updated: Aug 21, 2026, 02:10 AM

Technical Indicators

RSI (14-day)

75.43

Overbought

50-Day Moving Average

$92.65

26.08% above MA-50

200-Day Moving Average

$97.52

19.78% above MA-200

MACD Line

2.90

MACD Signal

0.96

MACD Histogram

1.94

Bullish

Q:What does BNTX's RSI value tell investors?
The RSI (Relative Strength Index) for BNTX is currently 75.43, indicating the stock is in overbought territory (above 70). This suggests strong recent buying pressure that may be unsustainable. While overbought conditions can persist in strong trends, traders often watch for RSI divergences or a drop below 70 as potential sell signals. Combined with the price being above the 50-day moving average, this confirms bullish conditions.
Q:How should traders interpret BNTX's MACD and moving average crossovers?
MACD analysis shows the MACD line at 2.90 above the signal line at 0.96, with histogram at 1.94. This bullish crossover suggests upward momentum is building. The wide histogram confirms strong momentum. The 50-day MA ($92.65) is below the 200-day MA ($97.52), forming a death cross pattern that often warns of extended weakness. Price is currently above both MAs, confirming strength.

Indicators last updated: Aug 21, 2026, 12:34 AM

Active Alerts

Alert Condition
RSI Threshold Cross
Threshold
70
Created
Aug 20, 2026, 04:26 PM
Alert Condition
Price falls below
Threshold
$87.00
Created
Aug 19, 2026, 08:42 AM

Stay Ahead of the Market with BioNTech SE Alerts

Set up price alerts for BioNTech SE and get notified instantly when the price hits your target. Never miss an important price movement again.